Abstract: A novel bacteriophage whose DNA molecule has endonuclease-sensitivity only in the DNA region carrying genetic information for the production of phage coat proteins can be obtained by isolating an endonuclease-resistant mutant from one of the lambdoid bacteriophages and mating the resulting bacteriophage with a lambdoid phage having endonuclease-sensitivity in the DNA region carrying genetic information for the production of coat proteins.
Abstract: Herpes virus was doubly mutated in two steps by treatment with phosphono formic acid and 5-ethyl-2'-desoxyuredine. In this way the pathogenicity of the herpes virus was so weakened that they are usable as vaccines.
Type:
Grant
Filed:
June 8, 1981
Date of Patent:
March 30, 1982
Inventors:
Kailash K. Gauri, Klaus Pressler, Klaus-Dirk Schenk
Abstract: There are disclosed novel vaccines for immunizing egg-laying birds against Egg Drop disease, a group of novel viruses (generically called EDS 76 virus) used in the preparation of such vaccines, and methods for immunizing egg-laying birds against Egg Drop disease or syndrome.
Abstract: A vaccine for infectious bovine rhinotracheitis (IBR) is prepared by non-ionic detergent extraction of IBR virus infected cells. The extracted viral envelope protein can be prepared in injectable dose form by combination with an oil-type adjuvant. The vaccine produces a high level of antibody response, and is capable of eliminating virus shed for animals infected after immunization.
Type:
Grant
Filed:
May 2, 1980
Date of Patent:
September 22, 1981
Assignee:
Iowa State University Research Foundation, Inc.
Abstract: This invention relates to a method of inactivating a non-A, non-B hepatitis agent by means of formalin utilized in extended treatment. The range of formalin treatment utilizes a concentration of 1:1,000-1:10,000, preferred 1:1,000, and the duration of treatment is from 24-120 hours at any temperature with a preferred 96 hours (4 days) at 37.degree..+-.4.degree. C. This formalin-treated or otherwise inactivated agent, or portions of the agent, may be later used to produce a vaccine against non-A, non-B hepatitis.
Type:
Grant
Filed:
May 16, 1980
Date of Patent:
September 22, 1981
Assignee:
The United States of America as represented by the Secretary of Health & Human Services
Abstract: Lyophilization time of live viral compositions is reduced and output per lyophilization unit is increased by lyophilizing a reduced volume of a more concentrated viral composition.
Abstract: A vaccine in parenteral dose form for preventing persistent feline leukemia viremia in cats is characterized by containing as the immunizing agent inactivated feline leukemia virus (FeLV) derived from the FL74 feline lymphoblastoid cell line.
Abstract: A rabies vaccine composition is disclosed which comprises a sterilized suspension of proteineous suckling mice or rat brain particles of injectable particle size laden with an amount of inactivated rabies virus which is equivalent to a virus titer of from at least about 10.sup.5 to about 10.sup.7 MLD.sub.50 per 0.01 milliliter thereof at a brain tissue concentration of from about 3 to about 6% by weight, in an aqueous buffer solution having a pH of between about 7.5 and about 8.4, and comprising an amount, dissolved therein, of between 0.03 and 0.08 moles per liter of a buffer composition comprising a mixture of an organic base of the formula ##STR1## wherein R.sub.1 and R.sub.2 each are hydrogen or CH.sub.2 CH.sub.2 OH and an acid addition salt thereof, preferably a mixture of tris (hydroxymethyl)amino methane and its hydrochloride. The vaccine composition exhibits a high potency and its pH value remains stable over a prolonged period of time.
Abstract: The present invention relates to the method of protecting dogs against canine parvoviruses. More specifically, the present invention relates to a method of producing an inactivated (killed) canine parvoviral vaccine from a native virulent strain of CPV for use as a vaccine in dogs against disease caused by virulent canine parvoviruses.